

Randomised, multicentre, double-blind, placebo-controlled phase 3 trials. ELEVATE UC 12 and ELEVATE UC 52.

Moderate to severe UC patients with inadequate response or intolerance to at least one approved UC therapy were randomised to: Once daily oral 2mg etrasimod or placebo. Proctitis were allowed to enter the study. Mesalazine and steroids(tapering) allowed.

Primary endpoints: Clinical remission at weeks 12 and 52.

### Results:

- Clinical remission at week 12: ELEVATE UC 12 25% etrasimod vs 15% placebo,  $p=0.026$ // ELEVATE UC52: 27% vs 7%,  $p<0.0001$
- Clinical remission week 52: ELEVATE UC 52, etrasimod 32% vs 7% placebo,  $p<0.0001$

### Conclusion:

Etrasimod was effective and well tolerated as an induction and maintenance therapy in patients with moderately to severely active ulcerative colitis.

## Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies

